QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.104.077883v1 jpet.104.077883v2 313/1/36    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Yamada, T. Articles by Itoh, M. Search for Related Content PubMed PubMed Citation Articles by Yamada, T. Articles by Itoh, M.

INFLAMMATION AND IMMUNOPHARMACOLOGY

Combination Therapy with an Angiotensin-Converting Enzyme Inhibitor and an Angiotensin II Receptor Blocker Synergistically Suppresses Chronic Pancreatitis in Rats

Okazaki City Medical Association, Public Health Center (T.Y.), Okazaki, Japan; and Departments of Internal Medicine and Bioregulation (A.K., S.N., T.A., T.O., H.O., T.N, T.J., M.I.), Experimental Pathophysiology and Tumor Biology (K.O., M.T., T.S.), and Gastroenterological Surgery (K.M.), Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan

We recently demonstrated that both lisinopril and candesartan, an angiotensin-converting enzyme inhibitor and angiotensin II type 1 receptor blocker, respectively, attenuate pancreatic inflammation and fibrosis in male Wistar Bonn/Kobori (WBN/Kob) rats. The purpose of the present study was to assess whether combination therapy with low doses of both, ineffective when given alone, might synergistically exert protective effects. Lisinopril, candesartan, or a combination of both in drinking water was administered to 10-week-old male WBN/Kob rats for 10 weeks. Parameters of inflammation and fibrosis, positive immunostaining for -smooth muscle actin, and gene expression of cytokine and growth factors were assessed, as well as circulating renin-angiotensin system components. Dose-dependent effects of combination therapy were also investigated. Only combination therapy attenuated gross alterations in the pancreas, as quantitatively confirmed by increases in pancreatic weights and decreases in myeloperoxidase activity, hydroxyproline content, histologic scores, relative fibrosis area, and relative area of -smooth muscle actin-positive cells. Combination therapy suppressed up-regulation of tumor necrosis factor-, platelet-derived growth factor-receptor , and transforming growth factor-1 mRNA in the pancreas. Dose dependence of combination therapy was recognized with reference to improvement in these parameters. The conclusions are that combination therapy synergistically alleviated pancreatic inflammation and fibrosis in male WBN/Kob rats. This effect may be related to suppression of tumor necrosis factor-, platelet-derived growth factor-receptor , and transforming growth factor-1 mRNA. Compared with the either therapy alone, combination therapy with an angiotensin-converting enzyme inhibitor and an angiotensin II type 1 receptor blocker may be more beneficial for treating chronic pancreatitis.

Address correspondence to: Dr. Tamaki Yamada, Okazaki City Medical Association, Public Health Center, 1-9-1 Tatsumi-nishi, Okazaki, Aichi, Japan, 444-0875. E-mail: t-yamada{at}okazaki-med.or.jp